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Heterozygous mutations in the X-linked MECP2 gene cause Rett syndrome, a severe neurodevelopmental disorder
of young females. Only one male presenting an MECP2 mutation has been reported; he survived only to age 1
year, suggesting that mutations in MECP2 are male lethal. Here we report a three-generation family in which two
affected males showed severe mental retardation and progressive spasticity, previously mapped in Xq27.2-qter. Two
obligate carrier females showed either normal or borderline intelligence, simulating an X-linked recessive trait. The
two males and the two obligate carrier females presented a mutation in the MECP2 gene, demonstrating that, in
males, MECP2 can be responsible for severe mental retardation associated with neurological disorders.
Several reports have shown that heterozygous de novo
mutations in theMECP2 gene (MIM 300005) causeRett
syndrome (MIM 312750), a sporadic severe neurodev-
elopmental disorder of young females (Bienvenu et al.
2000; Cheadle et al. 2000; De Bona et al. 2000; Huppke
et al. 2000; Kim and Cook 2000; Xiang et al. 2000).
The few known familial cases are due to the normal
fitness of nonpenetrant carriers who either bear the mu-
tation in a mosaic state or have a nonrandom X inac-
tivation (Amir et al. 1999; Wan et al. 1999). There have
been no reports of males with MECP2 mutations sur-
viving beyond age 1 year, which suggests the hypothesis
of lethality in males. However, since mutations in the
same gene often cause different phenotypes, we tested
whether MECP2 mutations may be found in males in
whom mental retardation segregated as an apparently
X-linked recessive trait.
In one of the families, segregating a very severe mental
retardation mapped in Xq27.2-qter, an MECP2 muta-
tion was found. In this family, mutations in other can-
didate genes (L1CAM, GDI, 16A, and SEX) were ex-
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cluded (Claes et al. 1997). Screening of theMECP2 gene
was performed by SSCP followed by direct sequencing
of PCR products showing abnormal migration, as re-
ported elsewhere (De Bona et al. 2000). A CrT tran-
sition in position 1216 was found in exon 3. The mu-
tation causes a substitution of glutamine (CAG) 406
with a stop codon (TAG). Since the mutation introduces
an AvrII restriction site, we tested all family members
by restriction analysis (fig. 1). The mutation was present
in the two affected males, as well as in the carrier fe-
males, and was absent in all unaffected males in the
family. The mutation was never described in Rett cases
and was not found among 100 chromosomes, analyzed
by AvrII digestion, from unaffected females.
Nonsense and frameshift mutations are supposed to
act in two different ways. In some cases, they have been
shown to cause production of a truncated protein. Al-
ternatively, they may cause a null phenotype because of
the so-called nonsense-mediated mRNA decay, a mech-
anism that recognizes and degrades mRNAs containing
nonsense mutations. To define the exact consequence of
the mutation C1216T, we performed semiquantitative
RT-PCR on RNA from lymphoblastoid cell lines from
one of the affected males and two unaffected controls.
After 35 PCR cycles, in the exponential phase of am-
plification, the amount of transcript was identical in the
patient and in the controls (fig. 2), indicating that the
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Figure 1 Segregation of the mutation in the family; 3% agarose
gel of AvrII-digested PCR products of segment D of exon 3 (396 bp)
obtained as reported elsewhere (De Bona et al. 2000). The CrT tran-
sition in position 1216 creates the “ccTagg” AvrII restriction site from
the normal “cccagg” sequence, generating two fragments of 213 and
183 bp. Line 1, molecular weight marker VI (Roche), following lines
as reported in pedigree above; ND p nondigested control.
Figure 2 Quantitative RT-PCR of total RNA from lympho-
blastoid cells of patient (OE) and male (XY) and female (XX) controls.
Primers were MECP-2 RT-S: 5′-CGC TCC ATC ATC CGT GAC-3′;
MECP-2 RS-A: 5′-TCT GCC AGT TCC TGG AGC-3′; GAPDH-F: 5′-
AACACAGTCCATGCCATCAC-3′; GAPDH-R: 5′-TCCACCACC
CTG TTG CTG TA-3′. The RT was done with () and without ()
retrotranscriptase, as described elsewhere (Bione et al. 1996), using 1
mg of total RNA. We amplified 2.5 ml of the RT reaction in a 50-ml
PCR reaction. C p PCR control without template DNA. PCR con-
ditions were the following: GAPDH: 5 min at 94C; 30 s at 94C, 30
s at 60C, and 30 s at 72C for 25 cycles; MECP-2: 5 min at 94C;
30 s at 94C, 30 s at 60C, and 30 s at 72C for 35 cycles.
transcript is not degraded and that a truncated protein
may be produced.
In the few familial cases of Rett syndrome, nonpe-
netrant females have nonrandom X inactivation. We
studied X inactivation in DNA from blood cells of both
carrier females (Allen et al. 1992). The assay showed
balanced X inactivation in both females (fig. 3). Band
intensities were measured: the ratio between the two
alleles was 56:44 in one female and 60:40 in the second.
A detailed phenotypic analysis of the family has been
reported elsewhere (Claes et al. 1997). In brief, males
showed delayed development (first steps at 2–5.5 years)
and were never able to speak. They showed facial hy-
potonia and sialorrhea and a habitus suggesting com-
plicated spastic paraplegia; their head circumferences
were at the 75th–90th percentile. One of them had cho-
reoathetotic movements in the right arm, a global brady-
arrhythmia as indicated by electroencephalogram, and
bilateral juvenile cataract; he was confined to a wheel-
chair and died from pneumonia at age 39 years. A thor-
ough phenotypic analysis of the family and comparison
with signs of Rett syndrome reveals some similarities,
including absence of language, ataxic gait, seizures,
grinding of teeth, and sialorrhea (table 1). Moreover,
spastic paraparesis is a frequent end-stage finding of
most cases of Rett syndrome. Among salient differences
are the absence (1) of growth retardation, (2) of loss of
acquired purposeful hand skills, and (3) of acquired mi-
crocephaly. The latter is one of the major diagnostic
criteria and contrasts with the macrocephaly of this fam-
ily. Moreover, stereotypic hand movements versus cho-
reoathetotic movements (present in only one male) and
constipation versus diarrhea are notable differences.
The only documented case of a male with anMECP2
mutation is an infant bearing an early truncating mu-
tation (806delG) who died, at age 1 year, from congen-
ital encephalopathy (Wan et al. 1999). Two other re-
ported cases were presumed to carry the same mutation
segregating in the family (Wan et al. 1999; I. Meloni,
M. Zappella, and A. Renieri, unpublished data). How-
ever, direct evidence was hampered by the absence of
biological samples from both boys.We now demonstrate
that hemizygosity of an MECP2 mutation may be com-
patible with life.
To our knowledge, the mutation described in the pre-
sent report has never been described in Rett patients.
The presence of a normal amount of MECP2 mRNA in
the patient analyzed suggests that a shorter protein, lack-
ing 80 amino acids at the C terminus, is synthesized.
The abnormal protein maintains the methyl-binding do-
main, the transcription repression domain, and only part
of the highly conserved histidine and proline-rich C-ter-
minal domain (Huppke et al. 2000). This C-terminal
region of the protein shows an overall homology of 35%
identity and 46% positivity in a 100–amino acid region
with two brain-specific factors, BF-1 and FKH4, which
are members of the fork head gene family (Murphy et
al. 1994). Moreover, the portion between amino acids
404 and 467 has been shown to facilitate MeCP2 bind-
ing to DNA (Chandler et al. 1999).
Altogether, our results suggest that a late truncation
of the MeCP2 protein (at amino acid 406) is compatible
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Table 1
Comparison of Signs Present in Rett Syndrome and in






Absence of language  
Seizures  
Spasticity  
Ataxic gait  
Sialorrhea  
Grinding of teeth   (Only one)
“Acquired” microcephaly  
Stereotypic hand movements  
Growth retardation  
Loss of acquired purposeful
hand skills  
Constipation   (Diarrhea)
Choreoathetotic movements   (Only one)
Facial hypotonia  
NOTE. A plus sign () indicates presence, and a minus
sign () indicates absence.
Figure 3 Results of X-inactivation assay: 6% polyacrylamide
silver-stained gel of PCR product of CAG repeat of the androgen-
receptor gene (Allen et al. 1992) from HpaII digested (D) and non-
digested (ND) DNA of the carrier females. Primers used for PCR
amplification were RS-6: 5′-GTC CAA GAC CTA CCG AGG AG-3′
and RS-7: 5′-CCA GGA CCA GGT AGC CTG TG-3′. Band intensities
were measured by Diversity Database program (Biorad), and the values
were corrected for preferential allele amplification (Pegoraro et al.
1994). Results showed a balanced X-inactivation: ∼56% of X-bearing
allele b active (b) and 44% of X-bearing allele a active (a) in themother
(right panel); ∼60% of normal paternal X active (c) and 40% of mu-
tated X active (a) in the daughter (left panel).
with some of the functions of MeCP2 and allows sur-
vival of the patients while nevertheless causing very se-
vere neurological defects. How the mutation described
in this paper is similar to the group of late frameshift
MECP2 mutations clustered between amino acids 384
and 455 cannot be determined at this point; unfortu-
nately, no studies could be performed on RNA stability
or the presence of a truncated protein in those patients.
The absence of a skewed X inactivation in carrier
females was perhaps the most striking result of this
study. Since a notable variation between tissues is re-
ported, the presence of a completely skewed X inacti-
vation in relevant tissues cannot be excluded. The milder
effect of the mutation described here could, however,
explain the lack of skewed pattern of X inactivation in
females. Alternatively, Rett syndrome may be considered
a digenic disease that develops when a de novo mutation
in theMECP2 gene occurs in the presence of a mutation
in another gene.
Following this digenic model, the MECP2 mutation
alone produces a recessive phenotype (as in this family),
whereas a mutation in the second gene alone may pro-
duce no phenotypic effect at all. The model fits with the
evidence that, in familial and sporadic Rett cases, the
X-inactivation pattern plays a central role in modulating
the disease (Amir et al. 2000; Van den Veyver and
Zoghbi 2000).
In conclusion, we suggest that mutations in the
MECP2 gene account for a subset of cases of apparently
recessive, very severe X-linked mental retardation as-
sociated with neurological disorders and that mutation
analysis of the MECP2 gene should also be performed
in mentally retarded males with progressive encepha-
lopathy. Extensive analysis of the MECP2 gene in such
cases will give an indication of the percentage of X-
linked mental retardation due to an MECP2 mutation.
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